Integra Ebit vs Research Development Analysis

IART Stock

USD 24.24 0.66 2.80%

Integra LifeSciences financial indicator trend analysis is infinitely more than just investigating Integra LifeSciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Integra LifeSciences is a good investment. Please check the relationship between Integra LifeSciences Ebit and its Research Development accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Integra LifeSciences Ebit account and Research Development. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Integra LifeSciences' Ebit and Research Development is 0.81. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Integra LifeSciences Holdings, assuming nothing else is changed. The correlation between historical values of Integra LifeSciences' Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Integra LifeSciences Holdings are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Integra LifeSciences' Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

0.81

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Ebit

Research Development

Most indicators from Integra LifeSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Integra LifeSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Integra LifeSciences' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 442.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 339.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	944.6M	970.3M	888.4M	458.0M
Total Revenue	1.5B	1.6B	1.5B	1.6B

Gross Profit Total Revenue

Integra LifeSciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Common Stock Total Equity	Short Term Investments	Short Term Debt
Total Assets		0.97	0.87	0.97	0.95	0.94	0.83	0.86	0.81	0.99	-0.27	0.83	0.96	0.81	0.99	0.93	0.68	0.78	0.99	0.85	0.96	0.97	0.98	0.85	0.68	0.02
Other Current Liab	0.97		0.89	0.91	0.87	0.95	0.73	0.81	0.76	0.96	-0.07	0.78	0.94	0.82	0.98	0.91	0.69	0.77	0.98	0.75	0.93	0.96	0.98	0.83	0.6	0.01
Total Current Liabilities	0.87	0.89		0.81	0.73	0.84	0.55	0.75	0.78	0.85	-0.23	0.77	0.84	0.83	0.86	0.74	0.84	0.87	0.88	0.56	0.86	0.87	0.89	0.9	0.37	0.01
Total Stockholder Equity	0.97	0.91	0.81		0.96	0.84	0.87	0.82	0.85	0.96	-0.34	0.86	0.92	0.8	0.92	0.92	0.65	0.79	0.92	0.88	0.96	0.92	0.91	0.84	0.7	0.05
Property Plant And Equipment Net	0.95	0.87	0.73	0.96		0.84	0.91	0.87	0.76	0.94	-0.27	0.79	0.91	0.73	0.91	0.95	0.53	0.66	0.9	0.93	0.92	0.87	0.88	0.76	0.76	0.0
Net Debt	0.94	0.95	0.84	0.84	0.84		0.69	0.88	0.62	0.95	-0.11	0.64	0.95	0.76	0.98	0.88	0.62	0.7	0.98	0.71	0.84	0.96	0.98	0.8	0.57	-0.03
Retained Earnings	0.83	0.73	0.55	0.87	0.91	0.69		0.71	0.77	0.8	-0.36	0.81	0.74	0.51	0.78	0.86	0.45	0.39	0.78	0.97	0.86	0.71	0.76	0.58	0.88	-0.1
Accounts Payable	0.86	0.81	0.75	0.82	0.87	0.88	0.71		0.55	0.87	-0.31	0.57	0.93	0.68	0.86	0.85	0.43	0.63	0.86	0.74	0.78	0.85	0.86	0.72	0.48	-0.15
Cash	0.81	0.76	0.78	0.85	0.76	0.62	0.77	0.55		0.76	-0.41	1.0	0.67	0.6	0.75	0.68	0.76	0.65	0.76	0.75	0.91	0.72	0.77	0.68	0.64	0.03
Non Current Assets Total	0.99	0.96	0.85	0.96	0.94	0.95	0.8	0.87	0.76		-0.25	0.78	0.97	0.81	0.99	0.93	0.64	0.79	0.99	0.84	0.93	0.99	0.98	0.86	0.66	0.03
Non Currrent Assets Other	-0.27	-0.07	-0.23	-0.34	-0.27	-0.11	-0.36	-0.31	-0.41	-0.25		-0.4	-0.22	-0.18	-0.21	-0.14	-0.21	-0.21	-0.2	-0.35	-0.3	-0.23	-0.2	-0.24	-0.15	0.02
Cash And Short Term Investments	0.83	0.78	0.77	0.86	0.79	0.64	0.81	0.57	1.0	0.78	-0.4		0.68	0.59	0.77	0.71	0.75	0.63	0.78	0.79	0.92	0.73	0.78	0.69	0.69	0.02
Net Receivables	0.96	0.94	0.84	0.92	0.91	0.95	0.74	0.93	0.67	0.97	-0.22	0.68		0.85	0.95	0.93	0.6	0.79	0.96	0.76	0.89	0.96	0.95	0.85	0.53	0.01
Common Stock Shares Outstanding	0.81	0.82	0.83	0.8	0.73	0.76	0.51	0.68	0.6	0.81	-0.18	0.59	0.85		0.79	0.8	0.62	0.88	0.79	0.52	0.78	0.83	0.78	0.87	0.25	0.28
Non Current Liabilities Total	0.99	0.98	0.86	0.92	0.91	0.98	0.78	0.86	0.75	0.99	-0.21	0.77	0.95	0.79		0.92	0.66	0.74	1.0	0.81	0.92	0.98	1.0	0.83	0.66	0.01
Inventory	0.93	0.91	0.74	0.92	0.95	0.88	0.86	0.85	0.68	0.93	-0.14	0.71	0.93	0.8	0.92		0.54	0.64	0.92	0.85	0.91	0.88	0.9	0.75	0.67	0.01
Other Current Assets	0.68	0.69	0.84	0.65	0.53	0.62	0.45	0.43	0.76	0.64	-0.21	0.75	0.6	0.62	0.66	0.54		0.68	0.69	0.38	0.77	0.64	0.7	0.68	0.4	0.02
Other Stockholder Equity	0.78	0.77	0.87	0.79	0.66	0.7	0.39	0.63	0.65	0.79	-0.21	0.63	0.79	0.88	0.74	0.64	0.68		0.75	0.44	0.73	0.82	0.74	0.87	0.21	0.21
Total Liab	0.99	0.98	0.88	0.92	0.9	0.98	0.78	0.86	0.76	0.99	-0.2	0.78	0.96	0.79	1.0	0.92	0.69	0.75		0.8	0.93	0.98	1.0	0.84	0.65	0.01
Property Plant And Equipment Gross	0.85	0.75	0.56	0.88	0.93	0.71	0.97	0.74	0.75	0.84	-0.35	0.79	0.76	0.52	0.81	0.85	0.38	0.44	0.8		0.84	0.76	0.78	0.62	0.88	-0.06
Total Current Assets	0.96	0.93	0.86	0.96	0.92	0.84	0.86	0.78	0.91	0.93	-0.3	0.92	0.89	0.78	0.92	0.91	0.77	0.73	0.93	0.84		0.88	0.93	0.8	0.69	0.0
Intangible Assets	0.97	0.96	0.87	0.92	0.87	0.96	0.71	0.85	0.72	0.99	-0.23	0.73	0.96	0.83	0.98	0.88	0.64	0.82	0.98	0.76	0.88		0.97	0.87	0.58	0.05
Short Long Term Debt Total	0.98	0.98	0.89	0.91	0.88	0.98	0.76	0.86	0.77	0.98	-0.2	0.78	0.95	0.78	1.0	0.9	0.7	0.74	1.0	0.78	0.93	0.97		0.83	0.63	-0.02
Common Stock Total Equity	0.85	0.83	0.9	0.84	0.76	0.8	0.58	0.72	0.68	0.86	-0.24	0.69	0.85	0.87	0.83	0.75	0.68	0.87	0.84	0.62	0.8	0.87	0.83		0.42	0.29
Short Term Investments	0.68	0.6	0.37	0.7	0.76	0.57	0.88	0.48	0.64	0.66	-0.15	0.69	0.53	0.25	0.66	0.67	0.4	0.21	0.65	0.88	0.69	0.58	0.63	0.42		-0.11
Short Term Debt	0.02	0.01	0.01	0.05	0.0	-0.03	-0.1	-0.15	0.03	0.03	0.02	0.02	0.01	0.28	0.01	0.01	0.02	0.21	0.01	-0.06	0.0	0.05	-0.02	0.29	-0.11

Click cells to compare fundamentals

Integra LifeSciences Account Relationship Matchups

Integra LifeSciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.3B	3.6B	3.8B	3.9B	3.8B	4.0B
Other Current Liab	156.2M	182.1M	198.3M	144.2M	176.3M	185.1M
Total Current Liabilities	331.3M	401.0M	340.0M	320.9M	307.0M	158.9M
Total Stockholder Equity	1.4B	1.5B	1.7B	1.8B	1.6B	1.7B
Property Plant And Equipment Net	431.9M	371.2M	396.2M	459.6M	496.4M	521.2M
Net Debt	1.3B	1.2B	1.1B	1.2B	1.4B	1.5B
Retained Earnings	398.6M	532.3M	698.6M	879.1M	946.9M	994.2M
Accounts Payable	113.1M	54.6M	61.8M	102.1M	92.3M	96.9M
Cash	198.9M	470.2M	513.4M	456.7M	276.4M	290.2M
Non Current Assets Total	2.4B	2.4B	2.6B	2.7B	2.7B	2.9B
Non Currrent Assets Other	11.2M	11.3M	10.0M	(510.2M)	26.0M	27.3M
Cash And Short Term Investments	198.9M	470.2M	513.4M	456.7M	309.1M	324.6M
Net Receivables	275.3M	225.5M	231.8M	263.5M	259.3M	272.3M
Common Stock Shares Outstanding	86.5M	85.2M	85.5M	83.5M	80.3M	67.2M
Liabilities And Stockholders Equity	3.3B	3.6B	3.8B	3.9B	3.8B	4.0B
Non Current Liabilities Total	1.6B	1.7B	1.8B	1.8B	1.9B	2.0B
Inventory	316.1M	310.1M	317.4M	324.6M	389.6M	409.1M
Other Current Assets	67.9M	231.4M	91.1M	116.8M	100.0M	51.5M
Other Stockholder Equity	1.1B	1.1B	1.0B	914.1M	655.2M	467.2M
Total Liab	1.9B	2.1B	2.1B	2.1B	2.2B	2.3B
Property Plant And Equipment Gross	431.9M	371.2M	711.1M	789.3M	863.8M	907.0M
Total Current Assets	858.2M	1.2B	1.2B	1.2B	1.1B	1.1B
Accumulated Other Comprehensive Income	(76.4M)	(74.1M)	(45.2M)	10.3M	(15.1M)	(15.9M)
Intangible Assets	1.0B	989.4M	1.1B	1.1B	1.1B	1.1B
Short Long Term Debt Total	1.5B	1.7B	1.7B	1.6B	1.7B	1.8B
Common Stock Total Equity	887K	893K	896K	905K	1.0M	528.7K
Short Term Investments	1.5M	4.7M	12K	16.7M	32.7M	34.3M
Short Term Debt	57.3M	159.1M	74.6M	67.4M	29.8M	28.3M
Common Stock	887K	893K	896K	905K	909K	547.5K
Other Liab	116.1M	131.2M	135.9M	201.8M	232.1M	243.7M
Other Assets	27.3M	168.6M	3.8B	63.2M	72.6M	69.0M
Long Term Debt	1.2B	1.4B	1.4B	1.3B	1.5B	749.7M
Treasury Stock	(119.9M)	(235.1M)	(234.4M)	(362.9M)	(326.6M)	(310.2M)
Property Plant Equipment	337.4M	287.5M	311.7M	311.3M	358.0M	375.9M
Current Deferred Revenue	4.8M	5.3M	5.3M	7.3M	8.5M	5.3M
Good Will	954.3M	932.4M	1.0B	1.0B	1.1B	1.1B
Net Tangible Assets	(569.1M)	(406.9M)	(474.2M)	(361.1M)	(325.0M)	(341.2M)
Retained Earnings Total Equity	398.6M	532.3M	698.6M	879.1M	1.0B	1.1B
Long Term Debt Total	1.2B	1.4B	1.4B	1.3B	1.5B	1.0B
Capital Surpluse	1.2B	1.3B	1.3B	1.3B	1.5B	1.0B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC